### Practical Clincal Use of Prascend®

#### Carol K. Clark, DVM, Dipl ACVIM Peterson & Smith Equine Hospital Ocala, FL



### **Alternative Title:**

The Nitty-Gritty, Down and Dirty, Only What I Need To Know, Don't Have Time for a Superfluous Internal Medicine Geek Fluff Talk on Prascend®



# Prascend® = Pergolide mesylate

INDICATION

# 

# For control of clinical signs of Equine Cushings Disease


### Equine Cushings Disease = PPID



PPID = Pituitary Pars Intermedia Dysfunction

- PI INHIBITED BY DOPAMINE from dopaminergic neurons in the hypothalamus
- Dopaminergic neurons undergo oxidative damage with aging (normal process)
- Accelerated process in some horses.....EMS
- As dopaminergic neurons are lost, melanotrophs are less inhibited
- Hyperplasia develops and melanotrophs secrete more hormones

(McFarlane et al., J Neuroendocrinol 2005)



### How does Prascend® work?

**Dopamine receptor agonist** 

Inhibits PI melanotrophs



### **Decreased homone production**





### Horses at Risk for PPID

Age **Older horses/ponies** > 15 years of age Breed **Ponies** Morgans, Pasos, Arabs, QH, Saddlebreds, Warmbloods, TWH No sex predilection EMS?





Pituitary Pars Intermedia Dysfunction (PPID) Clinical Presentation			
Early	Advanced		
Decreased athletic performance	Lethargy		
Change in attitude/lethargy	Generalized hypertrichosis		
Delayed haircoat shedding	Loss of seasonal haircoat shedding		
Regional hypertrichosis	Skeletal muscle atrophy		
Change in body conformation	Rounded abdomen		
Regional adiposity	Abnormal sweating (increased or decreased)		
Laminitis	Polyuria/polydipsia		
	Recurrent infections (e.g. sole abscesses)		
	Regional adiposity		
	Absent reproductive cycle / infertility		
	Laminitis		
	Hyperglycemia		
	Neurologic deficit/blindness		

Prepared by the PPID Working Group:

Nicholas Frank (Group Coordinator), Frank Andrews, Ben Buchanan, Andy Durham, Janice Kritchevsky, Dianne McFarlane, and Hal Schott

**Atypical Clinical Signs /Cases** Regional hypertrichosis Recurrent infections Change of body conformation Fertility problems Horses with EMS at 10yr






## So Which Horses Need Prascend®?

### How Do I Diagnose PPID?









# Equine Cushings Disease = PPID





#### **Current Tests Good for Advanced Disease**

Not Good for Early Cases!!!!!!



### **Diagnosis by Treatment Trial**

### It's done for ulcers and EPM..why not?



### Treat for 30-90 days Look for improvement in signs



# Why is Prascend® better than compounded Pergolide?

Comparison of Pharmaceutical Equivalence for Compound Preparations of Pergolide Mesylate

Assess potency and stability of various formulations
Liquid, powder, and capsules in common use by practitioners (Francks, Roadrunner, Smartpak, Stokes, Wedgewood, Wickliffe.)

•Potency of the compound was determined at 0, 15, 30, 45 and 60 days post receipt of the drug stored at room temperature and under refrigeration

Stanley SD, Knych HD. Comparison of pharmaceutical equivalence for compound preparations of pergolide mesylate. Presented at: 56th Annual Convention of the American Association of Equine Practitioners; December 4–8, 20 Baltimore, MD.

# Why is Prascend® better than compounded Pergolide?

- Initial concentrations in all formulations were highly variable, many having concentrations well below the label claim.
- High degree of variation in concentrations <u>between 2</u> <u>containers of same product ordered from same</u> <u>pharmacy on the same date.</u>
- 57% of tested products <u>did not meet FDA</u> requirements for potency at onset of the study.
- 21% of liquid products were above the required potency after 15 days. <u>All liquid products were sub-potent by</u> <u>30 days.</u>
- The only solid product meeting the potency requirement after 60 days was determined to be 120% of the target potency concentration at the outset of the study.

Stanley SD, Knych HD. Comparison of pharmaceutical equivalence for compound preparations of pergolide mesylate. Presented at: 56th Annual Convention of the American Association of Equine Practitioners;



# Why is Prascend® better than compounded Pergolide?

Take Home Message:

Results from this study demonstrate differences in potency of the active ingredient, pergolide mesylate, in the various formulations/products obtained from different veterinary compounding pharmacies.

This could have important consequences both from an efficacy and toxicity standpoint.

Stanley SD, Knych HD. Comparison of pharmaceutical equivalence for compound preparations of pergolide mesylate. Presented at: 56th Annual Convention of the American Association of Equine Practitioners;



#### Dosage and Administration:

- Orally starting at 2.0 µg/kg once daily
- Adjust dose to effect, don't exceed 4.0 µg/kg Tablets are scored - dose to nearest <u>one-half</u> <u>tablet increment</u>

Body Weight (lbs)	Dosage	
	2.0 μg/kg	4.0 μg/kg
300–749	0.5 tablet	1.0 tablet
750–1,249	1.0 tablet	2.0 tablets
1,250–1,749	1.5 tablets	3.0 tablets
1,750–2,249	2.0 tablets	4.0 tablets



How to switch from compounded pergolide:
 Start at label dose. If 4-6mg/day, 1.5-2mg
 – Potency and ingredients NOT EQUAL

Baseline ACTH level

2/3 horses will maintain on starting dose





- Tips on Administration
- Most will eat w/ handful grain (TINY bitter pill)
- Dissolves in <15 seconds into pink solution.</p>
- Apple juice, corn syrup, cake icing, circus peanuts, carrots, apple slices, flavors, etc.
   If IR: sugar-free sweet treats

### Watch for "pergolide cloud/veil"

- Horses occasionally appear depressed when pergolide treatment is initiated; may show inappetance.
- Practical Approach:
- Stop treatment for 2-4 days
- 1/2 dose once daily for 2 days
- Increase to twice daily for 2 days
- Return to regular dose once daily





**Other Side Effects:** Increased arthritis pain (lack of endorphins) from PPID) "Hyperexcitability" Can decrease Prolactin





**Results of Prascend® Treatment Trial** Horses evaluated for 6 months: ■ 50% had ↓ACTH in 1 week Most had JACTH in 28 days 76% responded during 6 months Subset of non-responders followed 3yrs – normal

About 30% transient inappetance



### Results of Prascend® Treatment Trial

#### Percent of Animals with Improvement in Clinical Signs Relative to Baseline Scores

Clinical sign	Day 90 (%)	Day 180 (%)
	N=113	N=111*
Hirsutism	32.7%	89.2%
Hyperhidrosis	27.4%	42.3%
Polyuria/polydipsia	31%	34.2%
Muscle wasting	36.3%	46%

\*Two horses were withdrawn from the study prior to Day 180.



Economic Considerations in Using Prascend®

60 ct vs 160 ct boxes – All foil 10 packs

Can use Horse Owner Brochure as package insert for "trial samples"

PPID is not cured, it is managed

Prascend® can be cost effective by improving the horse's health



Management of PPID **Drug Therapy with Prascend®?** Screen for Insulin Resistance (IR) **Proper Nutrition** Hoof Care **Routine Dentistry** Deworming **Body Clipping** 



### Tyler-22 years





Courtesy of Hal Schott

Tyler, 22 years old. Back at work, and winning!

### THE END



### cclar@petersonsmith.com



